Efficacy of Human Papillomavirus 16 and 18 (HPV-16/18) AS04-Adjuvanted Vaccine against Cervical Infection and Precancer in Young Women: Final Event-Driven Analysis of the Randomized, Double-Blind PATRICIA Trial

被引：80

作者：

Apter, Dan ^{[1
]}

Wheeler, Cosette M. ^{[2
,3
]}

Paavonen, Jorma ^{[4
]}

Castellsague, Xavier ^{[5
]}

Garland, Suzanne M. ^{[6
,7
]}

Skinner, S. Rachel ^{[8
,9
]}

Naud, Paulo ^{[10
]}

Salmeron, Jorge ^{[11
,12
]}

Chow, Song-Nan ^{[13
]}

Kitchener, Henry C. ^{[14
]}

Teixeira, Julio C. ^{[15
]}

Jaisamram, Unnop ^{[16
]}

Limson, Genara ^{[17
]}

Szarewski, Anne ^{[18
]}

Romanowski, Barbara ^{[19
]}

Aoki, Fred Y. ^{[20
]}

Schwarz, Tino F. ^{[21
,22
]}

Poppe, Willy A. J. ^{[23
]}

Xavier Bosch, F. ^{[24
]}

Mindel, Adrian ^{[25
]}

De Sutter, Philippe

Hardt, Karin ^{[26
,27
]}

Zahaf, Toufik ^{[26
,27
]}

Descamps, Dominique ^{[26
,27
]}

Struyf, Frank ^{[26
,27
]}

Lehtinen, Matti ^{[28
]}

Dubin, Gary ^{[29
]}

机构：

[1] Sexual Hlth Clin, Family Federat Finland, Helsinki, Finland

[2] Univ New Mexico, Hlth Sci Ctr, Dept Pathol, Albuquerque, NM 87131 USA

[3] Univ New Mexico, Hlth Sci Ctr, Dept Obstet & Gynecol, Albuquerque, NM 87131 USA

[4] Univ Helsinki, Dept Obstet & Ginecol, Helsinki, Finland

[5] Hosp Llobregat, Biomed Res Ctr Network Epidemiol & Publ Hlth CIBE, DIBELL, ICO,Canc Epidemiol Res Program, Catalonia, Spain

[6] Univ Melbourne, Royal Womens Hosp, Murdoch Childrens Res Inst, Microbiol & Infect Dis Dept, Melbourne, Vic, Australia

[7] Univ Melbourne, Murdoch Childrens Res Inst, Dept Obstet & Gynaecol, Melbourne, Vic, Australia

[8] Telethon Inst Child Hlth Res, Vaccine Trials Grp, Perth, WA, Australia

[9] Univ Sydney, Childrens Hosp Westmead, Discipline Paediat & Child Hlth, Sydney, NSW 2006, Australia

[10] Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil

[11] Inst Mexicano Seguro Social, Unidad Invest Epidemiol, Cuernavaca, Morelos, Mexico

[12] Inst Mexicano Seguro Social, Serv Salud, Cuernavaca, Morelos, Mexico

[13] Natl Taiwan Univ, Coll Med & Hosp, Dept Obstet & Gynecol, Taipei 10764, Taiwan

[14] St Marys Hosp, Cent Manchester Univ Hosp NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester M13 0JH, Lancs, England

[15] Univ Estadual Campinas, Campinas, SP, Brazil

[16] Chulalongkorn Univ, Fac Med, Dept Obstet & Gynaecol, Bangkok 10330, Thailand

[17] Univ Philippines, Philippine Gen Hosp, Coll Med, Makati Med Ctr, Makati, Philippines

[18] Queen Mary Univ London, Ctr Canc Prevent, Wolfson Inst Prevent Med, London, England

[19] Univ Alberta, Edmonton, AB, Canada

[20] Univ Manitoba, Winnipeg, MB, Canada

[21] Univ Wurzburg, Acad Teaching Hosp, Stiftung Juliusspital, Cent Lab, Wurzburg, Germany

[22] Univ Wurzburg, Acad Teaching Hosp, Stiftung Juliusspital, Vaccinat Ctr, Wurzburg, Germany

[23] Univ Hosp KU Leuven Gasthuisberg, Dept Gynaecol, Leuven, Belgium

[24] Network Cooperat Canc Res RTICC, Inst Catala Oncol, IDIBELL, Canc Epidemiol Res Program, Catalonia, Spain

[25] Ctr AIDS Programme Res Soth Africa, Durban, South Africa

[26] Vrije Univ Brussel, Univ Ziekenhuis Brussel, Afdelingshoofd Gynaecol Oncol, Brussels, Belgium

[27] GSK Vaccines, Wavre, Belgium

[28] Univ Tampere, Sch Publ Hlth, FIN-33101 Tampere, Finland

[29] GSK Vaccines, King Of Prussia, PA USA

来源：

CLINICAL AND VACCINE IMMUNOLOGY | 2015年 / 22卷 / 04期

关键词：

OF-STUDY ANALYSIS; PARTICLE VACCINE; HPV-VACCINATION; FOLLOW-UP; TYPE-16; CANCER; PREVALENCE; SAFETY; IMMUNIZATION; PREVENTION;

D O I：

10.1128/CVI.00591-14

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We report final event-driven analysis data on the immunogenicity and efficacy of the human papillomavirus 16 and 18 ((HPV16/18) AS04-adjuvanted vaccine in young women aged 15 to 25 years from the PApilloma TRIal against Cancer In young Adults (PATRICIA). The total vaccinated cohort (TVC) included all randomized participants who received at least one vaccine dose (vaccine, n = 9,319; control, n = 9,325) at months 0, 1, and/or 6. The TVC-naive (vaccine, n = 5,822; control, n = 5,819) had no evidence of high-risk HPV infection at baseline, approximating adolescent girls targeted by most HPV vaccination programs. Mean follow-up was approximately 39 months after the first vaccine dose in each cohort. At baseline, 26% of women in the TVC had evidence of past and/or current HPV-16/18 infection. HPV-16 and HPV-18 antibody titers postvaccination tended to be higher among 15- to 17-year-olds than among 18- to 25-year-olds. In the TVC, vaccine efficacy (VE) against cervical intraepithelial neoplasia grade 1 or greater (CIN1+), CIN2+, and CIN3+ associated with HPV-16/18 was 55.5% (96.1% confidence interval [CI], 43.2, 65.3), 52.8% (37.5, 64.7), and 33.6% (-1.1, 56.9). VE against CIN1+, CIN2+, and CIN3+ irrespective of HPV DNA was 21.7% (10.7, 31.4), 30.4% (16.4, 42.1), and 33.4% (9.1, 51.5) and was consistently significant only in 15- to 17-year-old women (27.4% [10.8, 40.9], 41.8% [22.3, 56.7], and 55.8% [19.2, 76.9]). In the TVC-naive, VE against CIN1+, CIN2+, and CIN3+ associated with HPV-16/ 18 was 96.5% (89.0, 99.4), 98.4% (90.4, 100), and 100% (64.7, 100), and irrespective of HPV DNA it was 50.1% (35.9, 61.4), 70.2% (54.7, 80.9), and 87.0% (54.9, 97.7). VE against 12-month persistent infection with HPV-16/18 was 89.9% (84.0, 94.0), and that against HPV-31/33/45/51 was 49.0% (34.7, 60.3). In conclusion, vaccinating adolescents before sexual debut has a substantial impact on the overall incidence of high-grade cervical abnormalities, and catch-up vaccination up to 18 years of age is most likely effective.

引用

页码：361 / 373

页数：13

共 50 条

[31] Safety and Immunogenicity of the HPV-16/18 AS04-adjuvanted Vaccine in 4-6-year-old Girls Results to Month 12 From a Randomized Trial
Lin, Lan
Macias Parra, Mercedes
Sierra, Victor Y.
Salas Cespedes, Albino
Angelica Granados, Maria
Luque, Adriana
Damaso, Silvia
Castrejon Alba, Maria Mercedes
Romano-Mazzotti, Luis
Struyf, Frank
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2018, 37 (04) : E93 - E102
[32] Safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in adolescents aged 12-15 years: Interim analysis of a large community-randomized controlled trial
Lehtinen, Matti
Eriksson, Tiina
Apter, Dan
Hokkanen, Mari
Natunen, Kari
Paavonen, Jorma
Pukkala, Eero
Angelo, Maria-Genalin
Zima, Julia
David, Marie-Pierre
Datta, Sanjoy
Bi, Dan
Struyf, Frank
Dubin, Gary
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2016, 12 (12) : 3177 - 3185
[33] Impact of HPV-16/18 AS04-adjuvanted vaccine on preventing subsequent infection and disease after excision treatment: post-hoc analysis from a randomized controlled trial
Zhao, Shuang
Hu, Shangying
Xu, Xiaoqian
Zhang, Xun
Pan, Qinjing
Chen, Feng
Zhao, Fanghui
BMC INFECTIOUS DISEASES, 2020, 20 (01)
[34] Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years
Romanowski, B.
de Borba, P. Colares
Naud, P. S.
Roteli-Martins, C. M.
De Carvalho, N. S.
Teixeira, J. C.
Aoki, F.
Ramjattan, B.
Shier, R. M.
Somani, R.
Barbier, S.
Blatter, M. M.
Chambers, C.
Ferris, D.
Gall, S. A.
Guerra, F. A.
Harper, D. M.
Hedrick, J. A.
Henry, D. C.
Korn, A. P.
Kroll, R.
Moscicki, A-B
Rosenfeld, W. D.
Sullivan, B. J.
Thoming, C. S.
Tyring, S. K.
Wheeler, C. M.
Dubin, G.
Schuind, A.
Zahaf, T.
LANCET, 2009, 374 (9706) : 1975 - 1985
[35] Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial
Einstein, Mark H.
Takacs, Peter
Chatterjee, Archana
Sperling, Rhoda S.
Chakhtoura, Nahida
Blatter, Mark M.
Lalezari, Jacob
David, Marie-Pierre
Lin, Lan
Struyf, Frank
Dubin, Gary
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (12) : 3435 - 3445
[36] Safety and Immunogenicity of Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine: A Randomized Trial in 10-25-Year-Old HIV-Seronegative African Girls and Young Women
Sow, Papa Salif
Watson-Jones, Deborah
Kiviat, Nancy
Changalucha, John
Mbaye, Khardiata Diallo
Brown, Joelle
Bousso, Kouro
Kavishe, Bazil
Andreasen, Aura
Toure, Macoumba
Kapiga, Saidi
Mayaud, Philippe
Hayes, Richard
Lebacq, Marie
Herazeh, Marjan
Thomas, Florence
Descamps, Dominique
JOURNAL OF INFECTIOUS DISEASES, 2013, 207 (11) : 1753 - 1763
[37] Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years Results from 2 randomized controlled trials
Zhu, Fengcai
Li, Juan
Hu, Yuemei
Zhang, Xiang
Yang, Xiaoping
Zhao, Hui
Wang, Junzhi
Yang, Jianguo
Xia, Guodong
Dai, Qinyong
Tang, Haiwen
Suryakiran, Pemmaraju
Datta, Sanjoy K.
Descamps, Dominique
Bi, Dan
Struyf, Frank
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (07) : 1795 - 1806
[38] AS04-Adjuvanted Human Papillomavirus (HPV) Types 16 and 18 Vaccine (Cervarix®) A Review of its Use in the Prevention of Premalignant Cervical Lesions and Cervical Cancer Causally Related to Certain Oncogenic HPV Types
McKeage, Kate
Romanowski, Barbara
DRUGS, 2011, 71 (04) : 465 - 488
[39] Human papillomavirus 16/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in 15-25 years old healthy Korean women
Kim, Seung Cheol
Song, Yong Sang
Kim, Young-Tae
Kim, Young Tak
Ryu, Ki-Sung
Gunapalaiah, Bhavyashree
Bi, Dan
Bock, Hans L.
Park, Jong-Sup
JOURNAL OF GYNECOLOGIC ONCOLOGY, 2011, 22 (02) : 67 - 75
[40] Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine Final analysis of a long-term follow-up study up to 9.4 years post-vaccination
Naud, Paulo S.
Roteli-Martins, Cecilia M.
De Carvalho, Newton S.
Teixeira, Julio C.
de Borba, Paola C.
Sanchez, Nervo
Zahaf, Toufik
Catteau, Gregory
Geeraerts, Brecht
Descamps, Dominique
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (08) : 2147 - 2162

← 1 2 3 4 5 →